What is HC Wainwright's Forecast for Pharvaris Q3 Earnings?

Key Points

• HC Wainwright lowered its Q3 2026 EPS forecast for Pharvaris to a loss of $0.92 per share from $0.76 previously, while maintaining a “Buy” rating. It expects a $3.41-per-share loss for full-year 2026.
• Pharvaris recently reported a Q2 loss of $0.81 per share, missing the consensus estimate of a $0.75 loss. Despite the earnings miss, the analyst consensus remains “Moderate Buy,” with an average price target of $51.08.
• Pharvaris shares opened at $35.32, near their 12-month high of $36.93, while several major institutions increased their holdings. However, company insiders sold 156,030 shares worth about $5.3 million during the last quarter.

Pharvaris N.V. (NASDAQ:PHVS - Free Report) - Equities researchers at HC Wainwright cut their Q3 2026 earnings per share estimates for shares of Pharvaris in a research note issued to investors on Friday, August 14th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.92) per share for the quarter, down from their previous estimate of ($0.76). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Pharvaris' Q4 2026 earnings at ($0.98) EPS, FY2026 earnings at ($3.41) EPS, Q1 2027 earnings at ($0.99) EPS, Q2 2027 earnings at ($0.89) EPS, Q3 2027 earnings at ($0.77) EPS, FY2027 earnings at ($3.30) EPS, FY2028 earnings at ($0.56) EPS and FY2029 earnings at $3.09 EPS.

Several other analysts also recently commented on the stock. Morgan Stanley lifted their target price on shares of Pharvaris from $41.00 to $46.00 and gave the stock an "overweight" rating in a report on Thursday, June 25th. New Street Research set a $60.00 price target on Pharvaris in a research note on Friday. Wells Fargo & Company began coverage on Pharvaris in a report on Wednesday, July 15th. They set an "overweight" rating and a $55.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a research report on Friday, July 17th. Finally, Guggenheim lifted their price objective on shares of Pharvaris from $39.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $51.08.

Pharvaris Trading Up 0.5%

NASDAQ PHVS opened at $35.32 on Tuesday. The stock has a 50 day moving average of $33.79 and a 200-day moving average of $30.17. Pharvaris has a 12 month low of $20.65 and a 12 month high of $36.93. The company has a market cap of $2.31 billion, a PE ratio of -11.58 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06).

Institutional Trading of Pharvaris

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in shares of Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company's stock worth $952,000 after acquiring an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc grew its stake in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock worth $203,000 after purchasing an additional 1,695 shares during the period. Amundi grew its stake in Pharvaris by 2,741,600.0% during the second quarter. Amundi now owns 27,417 shares of the company's stock worth $489,000 after purchasing an additional 27,416 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company's stock worth $860,000 after purchasing an additional 7,879 shares in the last quarter.

Insider Activity at Pharvaris

In related news, Director Viviane Monges sold 9,667 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $30.29, for a total value of $292,813.43. Following the completion of the sale, the director directly owned 5,500 shares in the company, valued at $166,595. This represents a 63.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO David W. Nassif sold 10,000 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $30.31, for a total value of $303,100.00. Following the completion of the sale, the chief financial officer directly owned 120,300 shares of the company's stock, valued at approximately $3,646,293. The trade was a 7.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 156,030 shares of company stock valued at $5,304,914 in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source